Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.77), $0.36 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $201.5 million versus the consensus estimate of $198.61 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.